Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

NRX Pharmaceuticals Q3 2026 Results: Net Loss of $2.17M, Loss Narrows

NRX Pharmaceuticals reported a net loss of $20.1 million for the nine months ended September 30, 2026, an improvement from the $29.0 million loss in the prior year period. The company significantly increased its cash position to $19.8 million through various equity offerings, while net patient service revenue grew to $3.3 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.20.2
Net income-2.2-5.9
EPS (diluted, $ a share)$-0.05$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+395.9%
Source

10-Q filed with the SEC, NASDAQ: NRXP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

NRX Pharmaceuticals, Inc.: key numbers

Share price
$2.15Close, Nov 16
Market cap
$93.1M
Shares outstanding
43.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from NRX Pharmaceuticals, Inc.

All →
8:06 AM ET 8-K
Regulatory Approval

NRX Pharmaceuticals Regulatory Approval

NRx Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine ahead of its November 10 goal date. The product is an American-manufactured formulation that eliminates the use of benzethonium chloride, a preservative the FDA has declined to designate as safe. The company aims to address the ongoing national shortage of ketamine using modern high-volume manufacturing technology in partnership with Nephron Pharmaceuticals.

“We are excited to bring Preservative-Free Ketamine to market and to give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in multiple product categories by the US Food and Drug Administration.”

Jonathan Javitt, MD, MPH, the company’s Chairman and Chief Executive Officer
5:16 PM ET 8-K
Shareholder Meeting

NRX Pharmaceuticals Shareholder Meeting

NRx Pharmaceuticals has scheduled its 2026 Annual Meeting of Stockholders for December 17, 2026, to be held in a virtual-only format. The company established October 28, 2026, as the record date and set October 25, 2026, as the new deadline for stockholder proposals and director nominations. These deadlines were revised because the meeting date is more than 30 days from the anniversary of the previous year's annual meeting.

5:01 PM ET 8-K
Contract Win

NRX Pharmaceuticals Wins $11.2M Contract from Defense Advanced Research Projects Agency

NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, was awarded an $11.2 million prime contract from DARPA to conduct the SPARC-TMS clinical trial. The trial evaluates a single-day treatment protocol combining robotic neuro-navigated transcranial magnetic stimulation with the company's investigational drug, NRX-101, for treatment-resistant depression. The contract includes an initial obligation of $6.7 million with additional funding subject to appropriations and performance milestones.

Value
$11.2M
Counterparty
Defense Advanced Research Projects Agency (DARPA)
Term
18 months
6:02 AM ET 8-K
Business Update

NRX Pharmaceuticals Business Update

NRx Pharmaceuticals received notification from the FDA reclassifying a previously 'Major' amendment to its Abbreviated New Drug Application (ANDA) for preservative-free ketamine as a 'Minor' amendment. This reclassification accelerates the regulatory timeline, resulting in a revised GDUFA goal date of November 10, 2026.

Counterparty
FDA Office of Generic Drugs
8:01 AM ET 8-K
Investor Presentation

NRX Pharmaceuticals Investor Presentation

NRx Pharmaceuticals filed a formal investor presentation deck as an exhibit to be used in meetings with investors and analysts. The presentation provides a strategic update on the company's pharmaceutical pipeline and business operations.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.